Evidence map›Paper›PMID 38979201›Full record

ArticlebioRxiv : the preprint server for biology2024

Scalable intracellular delivery via microfluidic vortex shedding enhances the function of chimeric antigen receptor T-cells.

Brandon J Sytsma, Vincent Allain, Struan Bourke, Fairuz Faizee, Mohsen Fathi, Rebecca Berdeaux, Leonardo M R Ferreira, W Jared Brewer, Lian Li, Fong L Pan and 6 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Brandon J SytsmaIndee Labs, Berkeley, CA, USA.ORCID 0009-0003-1342-3424
Vincent AllainGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-1068-7892
Struan BourkeIndee Labs, Berkeley, CA, USA.ORCID 0000-0003-1534-6736
Fairuz FaizeeIndee Labs, Berkeley, CA, USA.ORCID 0000-0003-2853-4365
Mohsen FathiCellChorus, Houston, TX, United States.
Rebecca BerdeauxCellChorus, Houston, TX, United States.ORCID 0000-0002-9929-1711
Leonardo M R FerreiraIndee Labs, Berkeley, CA, USA.ORCID 0000-0003-2491-9866
W Jared BrewerIndee Labs, Berkeley, CA, USA.ORCID 0000-0003-2217-2172
Lian LiIndee Labs, Berkeley, CA, USA.
Fong L PanIndee Labs, Berkeley, CA, USA.
Allison G RothrockGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.
William A NybergGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-9982-1305
Zhongmei LiGladstone-UCSF Institute of Genomic Immunology, San Francisco, CA, USA.ORCID 0000-0002-5647-944X
Leah H WilsonIndee Labs, Berkeley, CA, USA.
Justin EyquemIndee Labs, Berkeley, CA, USA.ORCID 0000-0001-8262-1190
Ryan S PawellIndee Labs, Berkeley, CA, USA.ORCID 0000-0002-6156-2918

Funding

Tumor BiologyP30CA125123 · NCI · BAYLOR COLLEGE OF MEDICINE · PI Suzanne AW Fuqua · 2007 to 2026
$73.9M
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
Integrated assays of single-cell dynamics and molecular phenotype for cell therapy manufacturingR44TR005137 · NCATS · CELLCHORUS INC. · PI Rebecca L Berdeaux · 2024 to 2026
$2.4M
Dynamic single-cell analysis instrument to evaluate immune cell functionR44GM149106 · NIGMS · CELLCHORUS INC. · PI COOPER, LAURENCE J.N. · 2023 to 2025
$2.3M
BD Biosciences Special Order LSRIIS10RR024574 · NCRR · BAYLOR COLLEGE OF MEDICINE · PI LUMPKIN, ELLEN A · 2009 to 2009
$430k
Microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies75N91020C00030 · NCI · INDEE, INC · PI JARRELL, JUSTIN · 2020 to 2020
$399k
Rapid, single-step precision engineering and pre-clinical evaluation of chimeric antigen receptor Regulatory T cells for Type 1 diabetesR43DK133029 · NIDDK · INDEE, INC · PI PAWELL, RYAN · 2022 to 2022
$310k
NCATS NIH HHS R44 TR005137NCI NIH HHS 75N91020C00030NCI NIH HHS P30 CA125123NCRR NIH HHS S10 RR024574NIDDK NIH HHS P30 DK063720NIDDK NIH HHS R43 DK133029NIGMS NIH HHS R44 GM149106
6 · The paper itself

Abstract

Adoptive chimeric antigen receptor T-cell (CAR-T) therapy is transformative and approved for hematologic malignancies. It is also being developed for the treatment of solid tumors, autoimmune disorders, heart disease, and aging. Despite unprecedented clinical outcomes, CAR-T and other engineered cell therapies face a variety of manufacturing and safety challenges. Traditional methods, such as lentivirus transduction and electroporation, result in random integration or cause significant cellular damage, which can limit the safety and efficacy of engineered cell therapies. We present hydroporation as a gentle and effective alternative for intracellular delivery. Hydroporation resulted in 1.7- to 2-fold higher CAR-T yields compared to electroporation with superior cell viability and recovery. Hydroporated cells exhibited rapid proliferation, robust target cell lysis, and increased pro-inflammatory and regulatory cytokine secretion in addition to improved CAR-T yield by day 5 post-transfection. We demonstrate that scaled-up hydroporation can process 5 x 10

Indexed as

AAVCAR-TCell TherapyCRISPRCytokineGene editingIntracellular deliveryMicrofluidicsSerial killingVortex shedding

Identifiers

PMID38979201
PMCPMC11230359

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.